Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases

The Actin Cytoskeleton in T Cell Activation

(2008) Janis K. Burkhardt et al.   Annual Review of Immunology

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

(2008) A. Ferrajoli et al.   BLOOD

CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet

(2008) Weiming Xu et al.   CLINICAL IMMUNOLOGY

Lenalidomide for the Treatment of B-Cell Malignancies

(2008) Asher A. Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia

(2008) Leslie A. Andritsos et al.   JOURNAL OF CLINICAL ONCOLOGY

NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G

(2008) G Maki et al.   LEUKEMIA